TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31152672

Group type: EXPERIMENTAL
Intervention: Green lentil chili (61.8 g)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Red lentil chili (54 g)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rice chili
Number of subjects: 24

Group type: COMPARATOR
Intervention: Muffin treatments (wheat replaced with lentils)
Number of subjects: 24
Study: 28158893

Group type: EXPERIMENTAL
Intervention: Curcumin (phytosomal form; 1000 mg/day in 2 divided doses)
Number of subjects: 102
Study: 25583274

Group type: EXPERIMENTAL
Intervention: Overground simulation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Treadmill simulation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both simulations
Number of subjects: 19
Study: 23865947

Group type: EXPERIMENTAL
Intervention: Crisis postcard intervention
Number of subjects: 761

Group type: COMPARATOR
Intervention: Control group (no postcard intervention)
Number of subjects: 761
Study: 21854150

Group type: EXPERIMENTAL
Intervention: UpToDate
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: First Consult
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: ACP PIER
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Essential Evidence Plus
Number of subjects: 112
Study: 19228872

Group type: EXPERIMENTAL
Intervention: CoQ(10) supplementation (200 mg/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 17454335

Group type: EXPERIMENTAL
Intervention: Home environmental assessment
Number of subjects: 177
Study: 15260084

Group type: EXPERIMENTAL
Intervention: 3 mg of oral tizanidine as premedication 60 minutes before arrival in the operating room
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo 60 minutes before arrival in the operating room
Number of subjects: 40
Study: 11784459

Group type: EXPERIMENTAL
Intervention: Happy mood condition
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Neutral mood condition
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Depressed mood condition
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Regular gamblers
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Regular gamblers (losing)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Regular gamblers (winning)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Non-regular gamblers
Number of subjects: 120
Study: 9175566

Group type: EXPERIMENTAL
Intervention: Cilazapril (n = 10)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Minoxidil combined with a diuretic (n = 10)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cilazapril + Minoxidil (n = 6)
Number of subjects: 26
Study: 1494770

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline 5 mg
Number of subjects: 20
Study: 2858710

Group type: EXPERIMENTAL
Intervention: 300 mg dipyridamole and 150 mg aspirin daily from 3 months' gestation onwards (group A)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (group B, no treatment)
Number of subjects: 102
Study: 31425580

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 377

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 377
Study: 29701072

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with Ologen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trabeculectomy with Mitomycin C
Number of subjects: 0
Study: 29090661

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy plus patent foramen ovale closure (with GORE® HELEX® Septal Occluder or GORE® CARDIOFORM Septal Occluder)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Antiplatelet therapy alone
Number of subjects: 664
Study: 26009785

Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) intervention
Number of subjects: 252

Group type: COMPARATOR
Intervention: Attention-control feedback
Number of subjects: 252
Study: 23747481

Group type: EXPERIMENTAL
Intervention: Vaniprevir 125 mg qd
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vaniprevir 600 mg qd
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vaniprevir 25 mg bid
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vaniprevir 75 mg bid
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vaniprevir 250 mg bid
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vaniprevir 500 mg bid
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vaniprevir 700 mg bid
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20736851

Group type: EXPERIMENTAL
Intervention: ACDF with PCB cage-plate system
Number of subjects: 52

Group type: COMPARATOR
Intervention: Laminoplasty
Number of subjects: 52
Study: 19243603

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (6 months)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 45
Study: 17285226

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 15163774

Group type: EXPERIMENTAL
Intervention: 4 percent albumin
Number of subjects: 6997

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 6997
Study: 11398777

Group type: EXPERIMENTAL
Intervention: Intraluminal papaverine application
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Topical papaverine application
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Periarterial papaverine application
Number of subjects: 150
Study: 9424060

Group type: EXPERIMENTAL
Intervention: Orderly electrocardiographic limb lead display
Number of subjects: 83

Group type: COMPARATOR
Intervention: Classical electrocardiographic limb lead display
Number of subjects: 83
Study: 8261557

Group type: EXPERIMENTAL
Intervention: Home-based maternal record (HBMR)
Number of subjects: 0
Study: 3529917

Group type: EXPERIMENTAL
Intervention: Canned baked beans
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Home-cooked (boiled) baked beans
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: D-glucose
Number of subjects: 6
Study: 2514152

Group type: EXPERIMENTAL
Intervention: Hypoxic gas inhalation (HC: FIO2 is 16.0% in N2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normoxic conditions (NC: FIO2 is 20.9%; i.e., air)
Number of subjects: 12
Study: 31913324

Group type: EXPERIMENTAL
Intervention: H‐HOPE intervention
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study: 31626644

Group type: EXPERIMENTAL
Intervention: Genetically determined serum urate levels
Number of subjects: 339256
Study: 28712103

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided interscalene brachial plexus block (IBPB) with 20 mL of 0.5% ropivacaine (group U)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation (PNS)‐confirmed IBPB with 20 mL of 0.5% ropivacaine (group N)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided, PNS‐confirmed IBPB (dual guidance) with 20 mL of 0.5% ropivacaine (group NU)
Number of subjects: 106
Study: 24722769

Group type: EXPERIMENTAL
Intervention: Intensive medical nutrition therapy (IMNT)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard nutrition support care (SNSC)
Number of subjects: 78
Study: 23695772

Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg daily for 2 weeks, then increased to maximum daily dose for 4 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Amlodipine (5 mg daily for 2 weeks, then increased to maximum daily dose for 4 weeks)
Number of subjects: 38
Study: 22080023

Group type: EXPERIMENTAL
Intervention: Zinc levels at 137, 309, and 655 mg/kg
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Lysine levels at 0.560, 0.612, 0.677, 0.749, and 0.851%
Number of subjects: 720
Study: 19097942

Group type: EXPERIMENTAL
Intervention: 90 microg/kg desmoteplase
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: 125 microg/kg desmoteplase
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 16490951

Group type: EXPERIMENTAL
Intervention: Citicoline 1 g/12 h for 2 weeks (orally or intravenously)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 14610756

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10868869

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 5487

Group type: COMPARATOR
Intervention: Control (nondiabetic patients without baseline proteinuria)
Number of subjects: 5487
Study: 9185396

Group type: EXPERIMENTAL
Intervention: Initiating Ovrette at six weeks postpartum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initiating Ovrette at return of menses or 6 months postpartum
Number of subjects: 0
Study: 1545000

Group type: EXPERIMENTAL
Intervention: Retroperitoneal (RP) approach
Number of subjects: 27

Group type: COMPARATOR
Intervention: Transperitoneal (TP) approach
Number of subjects: 27
Study: 3885316

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diatrizoate
Number of subjects: 0
Study: 29574126

Group type: EXPERIMENTAL
Intervention: EUS-guided biliary drainage (EUS-BD)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 67
Study: 27838224

Group type: EXPERIMENTAL
Intervention: Vismodegib (150 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Vismodegib (after crossover from placebo)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (initial assignment)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Vismodegib (continuous dosing)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Vismodegib (interrupted dosing)
Number of subjects: 41
Study: 25040354

Group type: EXPERIMENTAL
Intervention: Early placement (Ea)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Delayed placement (De)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Late placement (La)
Number of subjects: 63
Study: 22098444

Group type: EXPERIMENTAL
Intervention: TGD 300 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TGD 900 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20845295

Group type: EXPERIMENTAL
Intervention: 20 mg sublingual isosorbide dinitrate (ISDN)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 18431738

Group type: EXPERIMENTAL
Intervention: 1950 MHz UMTS (SAR 0.1 and 1 W/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pulsed 900 MHz GSM (1 W/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 15
Study: 15758007

Group type: EXPERIMENTAL
Intervention: Computer alert program
Number of subjects: 2506
Study: 11133742

Group type: EXPERIMENTAL
Intervention: Allogeneic BMT
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Autologous BMT
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 652
Study: 10366992

Group type: EXPERIMENTAL
Intervention: Tiagabine HCl 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Triazolam 0.125 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tiagabine HCl 10 mg with triazolam 0.125 mg
Number of subjects: 12
Study: 8575984

Group type: EXPERIMENTAL
Intervention: Yeast-rich selenium (200 micrograms Se/day for 12 weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sodium selenite (200 micrograms Se/day for 12 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 33
Study: 2471894

Group type: COMPARATOR
Intervention: Oxprenolol (monotherapy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Chlorthalidone (monotherapy)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of oxprenolol and chlorthalidone
Number of subjects: 120
Study: 1201766

Group type: EXPERIMENTAL
Intervention: Insulin 160 ng/min. (INS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin 160 ng/min. (INS) + Secretin 12 ng/min. (SEC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Secretin 12 ng/min. (SEC)
Number of subjects: 0
Study: 31765269

Group type: EXPERIMENTAL
Intervention: Single-Incision Robotic Colectomy (SIRC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Multiport Robotic Colectomy (MPRC)
Number of subjects: 40
Study: 31239690

Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study: 28894074

Group type: EXPERIMENTAL
Intervention: Mastery learning program for nursing skills
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study: 26385928

Group type: EXPERIMENTAL
Intervention: Educational materials on the rationale behind using financial incentives for smoking cessation during pregnancy
Number of subjects: 166

Group type: COMPARATOR
Intervention: Educational materials on car safety for pregnant women and young children
Number of subjects: 166
Study: 25111136

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS) and endoscopic deep biopsy using the ESD technique (40 patients)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Surgical resection after EUS without obtaining preoperative pathological diagnosis (28 patients)
Number of subjects: 68
Study: 22547592

Group type: EXPERIMENTAL
Intervention: Phased ipilimumab
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Concurrent ipilimumab
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 204
Study: 19276664

Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine (n = 182)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Placebo (n = 181)
Number of subjects: 363
Study: 17616769

Group type: EXPERIMENTAL
Intervention: Low-glycemic-load diet
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control diet (carbohydrate-dense foods)
Number of subjects: 43
Study: 15683145

Group type: EXPERIMENTAL
Intervention: 90-minute sleep-wake schedule (30 minutes in bed, 60 minutes awake) for 60 hours
Number of subjects: 35
Study: 11779599

Group type: EXPERIMENTAL
Intervention: Recombinant human FSH (Gonal‐F)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urinary FSH (Fertinex)
Number of subjects: 0
Study: 9696002

Group type: EXPERIMENTAL
Intervention: Sclerotherapy (Group 1)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (Group 2)
Number of subjects: 72
Study: 7858335

Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (Qb: 400 ml/min, Qd: 800 ml/min, time: 3.5 hours, 10 L hemofiltrate exchanges with Ringer's lactate or combination of Ringer's solution and saline using polysulfone membrane dialyzer)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hemodiafiltration
Number of subjects: 6
Study: 2561147

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg once a day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30289165

Group type: EXPERIMENTAL
Intervention: Conditional discrimination relational training task
Number of subjects: 21

Group type: COMPARATOR
Intervention: Relational training plus defusion procedure
Number of subjects: 21
Study: 28609608

Group type: EXPERIMENTAL
Intervention: Inhaled voriconazole (40 mg b.i.d. for 2 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral voriconazole (400 mg on day 1, 200 mg on day 2, b.i.d.)
Number of subjects: 12
Study: 25805212

Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 30
Study: 23350870

Group type: EXPERIMENTAL
Intervention: Intervention group (n=35)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study: 21315002

Group type: EXPERIMENTAL
Intervention: Hengyan medicinal recipe 50 ml, 3 times daily for 7 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group treated with western medicine
Number of subjects: 45
Study: 19692911

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) during physical therapy sessions
Number of subjects: 39

Group type: COMPARATOR
Intervention: No Virtual Reality (no VR) during physical therapy sessions
Number of subjects: 39
Study: 17338829

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation followed by resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primary surgery
Number of subjects: 0
Study: 15355469

Group type: EXPERIMENTAL
Intervention: Cat allergen peptide immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD4(+) CD25(+) T cells (both before and after therapy)
Number of subjects: 0
Study: 11695713

Group type: EXPERIMENTAL
Intervention: Sustained release formulation of acyclovir (200mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional formulation of acyclovir (100mg)
Number of subjects: 12
Study: 9333591

Group type: EXPERIMENTAL
Intervention: Magnesium (Mg2+)
Number of subjects: 0
Study: 2022560

Group type: EXPERIMENTAL
Intervention: rhGH treatment (0.07 U/kg body wt daily)
Number of subjects: 24
Study: 7211966

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31995784

Group type: EXPERIMENTAL
Intervention: Structured self-monitoring of blood glucose (SMBG) over 12 months
Number of subjects: 231
Study: 30108337

Group type: EXPERIMENTAL
Intervention: Low intensity Extracorporeal Shockwave Therapy (Li‐ESWT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low intensity Extracorporeal Shockwave Therapy (Li‐ESWT) and Sham therapy
Number of subjects: 20
Study: 28935843

Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab (1,400 mg cycles 2-8)
Number of subjects: 576

Group type: COMPARATOR
Intervention: Intravenous rituximab (375 mg/m2 cycles 1-8)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab
Number of subjects: 576

Group type: COMPARATOR
Intervention: Intravenous rituximab
Number of subjects: 576
Study: 25738573

Group type: EXPERIMENTAL
Intervention: DSL protocol
Number of subjects: 128
Study: 25056361

Group type: EXPERIMENTAL
Intervention: Shanchol vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dukoral vaccine
Number of subjects: 0
Study: 22491729

Group type: EXPERIMENTAL
Intervention: 8-week stress management program (relaxation breathing and progressive muscle relaxation, twice a day)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 8-week stress management program
Number of subjects: 61
Study: 20484772

Group type: EXPERIMENTAL
Intervention: Free grip choice for both hands
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preinstructed grip for right hand and free choice for left hand
Number of subjects: 0
Study: 18406492

Group type: EXPERIMENTAL
Intervention: Watching the video
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Using the hand mirror
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Shower card
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: American Cancer Society brochure
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Sample photographs
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Finding the health educator helpful
Number of subjects: 567
Study: 15840076

Group type: EXPERIMENTAL
Intervention: 30 minutes of music intervention
Number of subjects: 64

Group type: COMPARATOR
Intervention: Rest period (Control)
Number of subjects: 64
Study: 11936019

Group type: EXPERIMENTAL
Intervention: TETRActHIB vaccine
Number of subjects: 131
Study: 10357402

Group type: EXPERIMENTAL
Intervention: Etoposide, 120 mg/m2 i.v. on Days 1-3; 5-fluorouracil, 500 mg/m2 i.v. on Days 1-3; folinic acid, 300 mg/m2 i.v. on Days 1-3; GM-CSF 250 microg/m2/day for 14 days if Grade 4 neutropenia occurred.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Courses without GM-CSF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Courses with GM-CSF
Number of subjects: 30
Study: 8825274

Group type: EXPERIMENTAL
Intervention: Flunarizine (50 mg daily intravenous for 1 week, followed by 21 mg daily oral for week 2, and 7 mg daily oral for weeks 3-4)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Flunarizine (subgroup receiving treatment within 6 hours)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo (subgroup receiving treatment within 6 hours)
Number of subjects: 331
Study: 1582280

Group type: EXPERIMENTAL
Intervention: 800 micrograms of triamcinolone acetonide daily
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 1200 micrograms of triamcinolone acetonide daily
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 1600 micrograms of triamcinolone acetonide daily
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control (baseline measurements before treatment)
Number of subjects: 143
Study: 3932250

Group type: EXPERIMENTAL
Intervention: 48-hour tubing change
Number of subjects: 2

Group type: COMPARATOR
Intervention: No tubing change
Number of subjects: 2
Study: 30670528

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29329910

Group type: EXPERIMENTAL
Intervention: Graded exercise test (GXT) until exhaustion with different delay groups (0, 30, 60, 90 min after GXT)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Exercise for 35 min at 45-50%, 65-70%, or 85-90% of HRmax
Number of subjects: 95
Study: 26847689

Group type: EXPERIMENTAL
Intervention: LSD (75 µg, intravenously)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline, intravenously)
Number of subjects: 20
Study: 25261978

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 2443

Group type: EXPERIMENTAL
Intervention: High triglycerides
Number of subjects: 2443

Group type: EXPERIMENTAL
Intervention: Low HDL-C
Number of subjects: 2443

Group type: EXPERIMENTAL
Intervention: Elevated blood pressure
Number of subjects: 2443

Group type: EXPERIMENTAL
Intervention: High plasma glucose
Number of subjects: 2443

Group type: EXPERIMENTAL
Intervention: Central obesity
Number of subjects: 2443

Group type: EXPERIMENTAL
Intervention: No components of MetS
Number of subjects: 2443

Group type: EXPERIMENTAL
Intervention: At least two components of MetS
Number of subjects: 2443

Group type: EXPERIMENTAL
Intervention: Risk factors associated with MetS
Number of subjects: 2443